Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes

Stroke. 2006 Jul;37(7):1910-2. doi: 10.1161/01.STR.0000226923.48905.39. Epub 2006 Jun 1.

Abstract

Background and purpose: Hemorrhagic conversion after tissue plasminogen activator (tPA) stroke therapy has been linked with elevations in matrix metalloproteinase-9 (MMP-9) at the neurovascular interface. Here, we test the idea that statins may directly ameliorate tPA-induced MMP-9 dysregulation.

Methods: Recombinant human tPA (5 microg/mL) was added to primary rat cortical astrocytes. Zymography was used to quantify MMP-9 levels in conditioned media. Effects of simvastatin or the Rho kinase inhibitor Y-27632 were assessed by pretreating cells before tPA exposure.

Results: Simvastatin (1 to 10 micromol/L) significantly reduced tPA-induced MMP-9 in cortical astrocytes. This effect may be mediated via the Rho kinase pathway because tPA-induced activation of Rho signaling was suppressed by simvastatin, and tPA-induced MMP-9 levels were similarly reduced by the Rho kinase inhibitor Y-27632 (1 to 10 micromol/L).

Conclusions: Statins reduce tPA-induced MMP-9 dysregulation by inhibiting the Rho signaling pathway. Statins may ameliorate tPA-associated MMP imbalances in stroke.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology
  • Animals
  • Astrocytes / drug effects*
  • Astrocytes / enzymology
  • Cells, Cultured / drug effects
  • Cells, Cultured / enzymology
  • Cerebral Hemorrhage / etiology
  • Drug Evaluation, Preclinical
  • Enzyme Induction / drug effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Intracellular Signaling Peptides and Proteins
  • Matrix Metalloproteinase 2 / biosynthesis
  • Matrix Metalloproteinase 2 / genetics
  • Matrix Metalloproteinase 9 / biosynthesis*
  • Matrix Metalloproteinase 9 / genetics
  • Neuroprotective Agents / pharmacology*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Pyridines / pharmacology
  • Rats
  • Recombinant Proteins / pharmacology
  • Signal Transduction / drug effects*
  • Simvastatin / pharmacology*
  • Stroke / complications
  • Stroke / enzymology
  • rho-Associated Kinases

Substances

  • Amides
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Intracellular Signaling Peptides and Proteins
  • Neuroprotective Agents
  • Pyridines
  • Recombinant Proteins
  • Y 27632
  • Simvastatin
  • Protein Serine-Threonine Kinases
  • rho-Associated Kinases
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9